MD-clip trial

On the long term most patients with age-related macular degeneration (ARMD) will experience severe irreversible vision loss. These low vision patients might benefit from an enhanced spectacle (MD-clip), equipped with several features, such as a prism using the outside of the macula. Experience in daily practice has shown that the MD-clip improves visual functioning. To substantiate these findings, we have undertaken this study to investigate the effect of the MD-clip on quality of life (QOL), particularly when the vision is actually improved. Additionally, we study the vision enhanced by the MD-clip, as well as the burden caused by the disease. In this prospective, open-label, randomized controlled trial, patients were randomized assigned (1:1) to either the MD-clip group or the waiting list.

- The enhanced prism spectacle (MD-clip) will increase the Quality of Life in patients with severe macula degeneration
- The MD-clip will increase vision in patients with severe macula degeneration

baseline, and six weeks after initial visit.

The experimental groups wears the MD-clip 3 weeks, the control group receive the MD-Clip after the study